310 related articles for article (PubMed ID: 21730163)
1. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo.
Huang L; Yan Z; Liao X; Li Y; Yang J; Wang ZG; Zuo Y; Kawai H; Shadfan M; Ganapathy S; Yuan ZM
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):12001-6. PubMed ID: 21730163
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
Tian H; Tackmann NR; Jin A; Zheng J; Zhang Y
J Biol Chem; 2017 Dec; 292(52):21614-21622. PubMed ID: 29123033
[TBL] [Abstract][Full Text] [Related]
3. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
Wang X
Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
[TBL] [Abstract][Full Text] [Related]
5. MDMX is essential for the regulation of p53 protein levels in the absence of a functional MDM2 C-terminal tail.
Sanford JD; Yang J; Han J; Tollini LA; Jin A; Zhang Y
BMC Mol Cell Biol; 2021 Sep; 22(1):46. PubMed ID: 34551723
[TBL] [Abstract][Full Text] [Related]
6. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.
Zhang Y; Zeng SX; Hao Q; Lu H
Dev Biol; 2017 Mar; 423(1):34-45. PubMed ID: 28118981
[TBL] [Abstract][Full Text] [Related]
7. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53.
Gu J; Kawai H; Nie L; Kitao H; Wiederschain D; Jochemsen AG; Parant J; Lozano G; Yuan ZM
J Biol Chem; 2002 May; 277(22):19251-4. PubMed ID: 11953423
[TBL] [Abstract][Full Text] [Related]
8. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation.
Itahana K; Mao H; Jin A; Itahana Y; Clegg HV; Lindström MS; Bhat KP; Godfrey VL; Evan GI; Zhang Y
Cancer Cell; 2007 Oct; 12(4):355-66. PubMed ID: 17936560
[TBL] [Abstract][Full Text] [Related]
9. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
[TBL] [Abstract][Full Text] [Related]
10. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
11. Aberrant activation of p53 due to loss of MDM2 or MDMX causes early lens dysmorphogenesis.
Zhang Y; Zhang X; Lu H
Dev Biol; 2014 Dec; 396(1):19-30. PubMed ID: 25263199
[TBL] [Abstract][Full Text] [Related]
12. Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.
Ohtsubo C; Shiokawa D; Kodama M; Gaiddon C; Nakagama H; Jochemsen AG; Taya Y; Okamoto K
Cancer Sci; 2009 Jul; 100(7):1291-9. PubMed ID: 19432880
[TBL] [Abstract][Full Text] [Related]
13. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of the first small molecule inhibitor of MDMX.
Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
[TBL] [Abstract][Full Text] [Related]
15. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
16. Mouse modelling of the MDM2/MDMX-p53 signalling axis.
Tackmann NR; Zhang Y
J Mol Cell Biol; 2017 Feb; 9(1):34-44. PubMed ID: 28096294
[TBL] [Abstract][Full Text] [Related]
17. Validation of MdmX as a therapeutic target for reactivating p53 in tumors.
Garcia D; Warr MR; Martins CP; Brown Swigart L; Passegué E; Evan GI
Genes Dev; 2011 Aug; 25(16):1746-57. PubMed ID: 21852537
[TBL] [Abstract][Full Text] [Related]
18. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
19. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
20. Regulation of p53: a collaboration between Mdm2 and Mdmx.
Pei D; Zhang Y; Zheng J
Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
